Mesenchymal stem cell therapy for liver disease: full of chances and challenges
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Liver disease is a major health problem that endangers human health worldwide. Currently, whole organ allograft transplantation is the gold standard for the treatment of end-stage liver disease. A shortage of suitable organs, high costs and surgical complications limit the application of liver transplantation. Mesenchymal stem cell therapy has been considered as a promising alternative approach for end-stage liver disease. Some clinical trials have confirmed the effectiveness of MSC therapy for liver disease, but its application has not been promoted and approved. There are still many issues that should be solved prior to using MSC therapy in clinical applications. The types of liver disease that are most suitable for MSC application should be determined, and the preparation and engraftment of MSCs should be standardized. These may be bottlenecks that limit the use of MSCs. We investigated 22 completed and several ongoing clinical trials to discuss these questions from a clinical perspective. We also discussed the important mechanisms by which MSCs play a therapeutic role in liver disease. Finally, we also proposed novel prospective approaches that can improve the therapeutic effect of MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta
in 't Anker, P. S., Scherjon, S. A., Kleijburg‐van der Keur, C., de Groot‐Swings, G. M. J. S., Claas, F. H. J., Fibbe, W. E., & Kanhai, H. H. H. (2004) · STEM CELLS · doi:10.1634/stemcells.2004-0058 · Cited by 1,189
Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., Baan, C. C., Dahlke, M. H., & Hoogduijn, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00297 · Cited by 804
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492
Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
Lin, B., Chen, J., Qiu, W., Wang, K., Xie, D., Chen, X., Liu, Q., Peng, L., Li, J., Mei, Y., et al. (2017) · Hepatology · doi:10.1002/hep.29189 · Cited by 288
Higashiyama, R., Inagaki, Y., Hong, Y. Y., Kushida, M., Nakao, S., Niioka, M., Watanabe, T., Okano, H., Matsuzaki, Y., Shiota, G., et al. (2007) · Hepatology · doi:10.1002/hep.21477 · Cited by 261
Amer, M.-E. M., El-Sayed, S. Z., El-Kheir, W. A., Gabr, H., Gomaa, A. A., El-Noomani, N., & Hegazy, M. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283488b00 · Cited by 180
El-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179
Cited by
Organoid transplant approaches for the liver
Reza, H. A., Okabe, R., & Takebe, T. (2021) · Transplant International · doi:10.1111/tri.14128 · Cited by 39
“MSCs in the range of 10(5)–10(9) are infused by intravenous, intrahepatic, or intrasplenic injection; however, it is unclear whether this therapy contributes to liver regeneration in the long period [32,33].”
BackgroundInfluentialZhu, D., Sun, Z., Wei, J., Zhang, Y., An, W., Lin, Y., & Li, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450284 · Cited by 17
“13 Additionally, the aging, differentiation, and contamination issues caused by the massive expansion of MSCs in vitro do not guarantee the quality of MSCs injections.”
BackgroundCell therapy for end-stage liver disease: Current state and clinical challenge
Zhang, L., Deng, Y., Bai, X., Wei, X., Ren, Y., Chen, S., & Deng, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003332 · Cited by 12
“[46,47] 50] Particularly for individuals suffering from liver failure or cirrhosis, MSCs appear to be the most suitable option for improving hepatic fibrotic and inflammatory microenvironments.”
Kim, S., Lee, D. H., Park, H. W., Noh, K. M., Jangid, A. K., Park, H., Kim, G. J., & Kim, K. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158313 · Cited by 11
Tawfeek, G. A.-E., Kasem, H. A., & Elshoala, S. E. (2023) · Nanotheranostics · doi:10.7150/ntno.81019 · Cited by 8
“In the current study, we like to assess if curcumin preconditioning of MSCs can maintain this ameliorative effect and protect against return of the fibrosis which actually represent a critical challenge in use MSCs in therapy and still there is a controversy about the long term efficacy of stem cells, there many precl…”
Metadata
- Authors
- Yang, X., Meng, Y., Han, Z., Ye, F., Wei, L., & Zong, C.
- Venue
- Cell & Bioscience
- Published
- 2020-10-27
- Volume
- 10
- Issue
- 1
- Pages
- 123-123
- ISSN
- 2045-3701 (ISSN-L)
- OpenAlex
- W3096521674
- Cited by
- 101
- References
- 18
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cell therapy for liver disease: full of chances and challenges. https://app.cochat.ai/papers/10.1186/s13578-020-00480-6
- The paper
- Yang, X., Meng, Y., Han, Z., Ye, F., Wei, L., & Zong, C. (2020). Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell & Bioscience. https://doi.org/10.1186/s13578-020-00480-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.